深海冷泉链霉菌OUCLQ19-3次级代谢产物的研究

目的 探究深海冷泉来源微生物产生丰富次级代谢产物的潜力,挖掘具有抗多重耐药(multi-drug resistant, MDR)菌活性的次级代谢产物,为新型海洋药物研发提供先导化合物。方法 采用大规模发酵积累粗提物,利用有机溶剂萃取、C18反相硅胶开放柱层析、半制备高效液相等分离手段对发酵产物进行分离纯化,通过MS、NMR数据以及文献比对进行化合物的结构鉴定,进而对化合物进行抗MDR菌活性测试。结果 从深海冷泉来源链霉菌Streptomyces sp. OUCLQ19-3发酵产物中分离得到2个xiamycin类化合物,分别为xiamycin B(1)和xiamycin A(2)；活性结果显示,化合物1和2均无抗MDR菌活性。结论 深海冷泉来源链霉菌Streptomyces sp. OUCLQ19-3能够产生一系列丰富的次级代谢产物,具有潜在的药用价值,其活性化合物有待进一步挖掘。

Study on the secondary metabolites from cold-seep derived Streptomyces sp. OUCLQ19-3

Objective The purpose of this study was to explore the potential of cold-seep living microorganisms for producing antibacterial secondary metabolites against multi-drug resistant (MDR) strains, and to provide lead compounds for new marine drug development. Methods Using large-scale fermentation to accumulate crude extracts; The fermentation products were separated and purified by solvent extraction, C18 reversed-phase open column chromatography and semi-preparative High Performance Liquid Chromatography (HPLC); The structures of the compounds were elucidated by MS and NMR data as well as comparison with published literatures, and then the antibacterial activity of the compounds were tested. Results Two compounds were isolated from the fermentation broths of Streptomyces sp. OUCLQ19-3 and their structures were identified as xiamycin B (1) and xiamycin A (2). In the antibacterial assay, neither of them showed growth inhibition against MDR bacteria. Conclusion Streptomyces sp. OUCLQ19-3 from cold-seep area produces a variety of secondary metabolites, which might have potential for medicinal use. These bioactive compounds need to be further explored.